Measures of Rheumatoid Arthritis Disease Activity

To the Editor:

The article by Pincus and colleagues¹ and the accompanying editorial by Neogi and Felson² debate the relative merits of individual and composite measures of disease outcome in rheumatoid arthritis (RA). Composite indices have clear merits. Pincus and colleagues reported that the physician global assessment performed well, and it gains some support from Neogi and Felson, as to them it represents a form of composite index. However, the issue that neither tackles is, "Which physician?"

Extensive work has shown that physicians differ substantially in their assessments of the severity of disease³⁻⁵ and of change in response to therapy⁶. Figure 1⁶ illustrates the opinion of 38 rheumatologists who judged the progress of 5 patients following the initiation of disease modifying antirheumatic drug (DMARD) therapy. Although there are trends in outcomes for the patients, with Patient E faring better than Patient A, there is very wide variation between the assessments made by different rheumatologists. Patient C, for example, has some physicians considering there has been a substantial improvement, while others score a substantial deterioration.

These differences are just as great when restricted to "clinically important" changes in disease status⁶, and are stable over long periods⁷, but are not apparent in routine clinical practice, where patients are reviewed by individual clinicians who do not test their assessments against those of their peers. Further, even when such comparisons are undertaken, the reasons for disagreement are not apparent to those making different judgments⁸. (Analysis of these clinical judgments can help clinicians converge on a common approach^{8,9}.) One solution is to develop a policy on judging the severity of RA based on the collective opinions of many rheumatologists, as applied to substantial patient management decisions, such as when to change DMARD due to perceived lack of efficacy. This has been done, and from it emerged the Disease Activity Score¹⁰.

JOHN KIRWAN, MD, Academic Rheumatology Unit, Bristol Royal Infirmary, Bristol, BS2 8HW United Kingdom.
E-mail: john.kirwan@bristol.ac.uk. Address reprint requests to Prof. Kirwan.

REFERENCES

1. Pincus T, Amara I, Segurado OG, Bergman M, Koch GG. Relative efficiencies of physician/assessor global estimates and patient questionnaire measures are similar to or greater than joint counts to distinguish adalimumab from control treatments in rheumatoid arthritis clinical trials. *J Rheumatol* 2008;35:201-5.
2. Neogi T, Felson DT. Composite versus individual measures of disease activity in rheumatoid arthritis [editorial]. *J Rheumatol* 2008;35:185-7.
3. Kirwan JR, Chaput de Saintonge DM, Joyce CRB, Currey HLF. Clinical judgement in rheumatoid arthritis. II. Judging 'current disease activity' in rheumatoid arthritis. *Ann Rheum Dis* 1983;42:648-51.
4. Kirwan JR, Bellamy N, Condon H, Buchanan WW, Barnes CG. Judgment of 'current disease activity' in rheumatoid arthritis — an international comparison. *J Rheumatol* 1983;10:901-5.
5. Kirwan JR, Brooks PM, Currey HLF. Measuring physicians' judgement — The use of clinical data by Australian rheumatologists. *Aust NZ J Med* 1985;15:738-44.
6. Kirwan JR, Chaput de Saintonge DM, Joyce CRB, Currey HLF. Clinical judgement in rheumatoid arthritis. III. British rheumatologists' judgements of 'change in response to therapy'. *Ann Rheum Dis* 1984;43:686-94.
7. Kirwan JR, Currey HLF. Clinical judgement in rheumatoid arthritis. IV. Rheumatologists' judgements are stable over long periods. *Ann Rheum Dis* 1984;43:695-7.
8. Kirwan JR, Chaput de Saintonge DM, Joyce CRB, Holmes J, Currey HLF. Inability of rheumatologists to describe their true policies for assessing rheumatoid arthritis. *Ann Rheum Dis* 1986;45:156-61.
9. Kirwan JR, Barnes CG, Davies P, Currey HLF. Analysis of clinical judgement helps to improve agreement in the assessment of rheumatoid arthritis. *Ann Rheum Dis* 1988;47:138-43.
10. van der Heijde DFM, van 't Hof MA, van Riel PLCM, et al. Judging disease activity in clinical practice in rheumatoid arthritis: first step in the development of a disease activity score. *Ann Rheum Dis* 1990;49:916-20.

J Rheumatol 2009;36:2; doi:10.3899/jrheum.080923

Figure 1. The opinion of 38 rheumatologists on the change in disease status of 5 patients with RA after initiation of DMARD therapy.